Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
SAN FRANCISCO and SUZHOU, Chin…
SAN FRANCISCO and SUZHOU, Chin…
LAS VEGAS, Jan. 1, 2025 /PRNew…
HANGZHOU, China, Jan. 1, 2025 …
SINGAPORE, Jan. 1, 2025 /PRNew…
NEW YORK, Jan. 1, 2025 /PRNews…
CHANGZHOU, China, Jan. 1, 2025…
SHENZHEN, China, Jan. 1, 2025 …
SINGAPORE, Jan. 1, 2025 /PRNew…
BEIJING, Dec. 31, 2024 /PRNews…